(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Reveal Stowed away Open Record Rewards - 2Understanding climate change in America: Skepticism, dogmatism and personal experience
- 3Climbing Mount Everest: An Individual Victory
- 4Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- 5Viable Monetary Tips to Advance Your Monetary Circumstance
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- How to get tickets for AC/DC's 2026 'Power Up' Tour
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- Fetterman says he's back home after a fall put the Pennsylvania senator in the hospital
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- African nations push to recognize crimes of colonialism in Algeria
- The Most Moving TED Talks You Want to Watch
- Munich Security Conference chief defends inviting AfD lawmakers
- How comfort foods trigger pleasure in our brains
